venetoclax + chemotherapy

This combination refers to the use of **venetoclax**, a selective BCL-2 inhibitor, in combination with **chemotherapy regimens** for the treatment of hematologic malignancies, most notably **acute myeloid leukemia (AML)** and other leukemias. Venetoclax targets and inhibits the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), restoring apoptosis in cancer cells dependent on this survival pathway. When combined with various chemotherapy agents—including **azacitidine** (a hypomethylating agent), **decitabine** (another hypomethylating agent), or **low-dose cytarabine (LDAC)**, or with traditional regimens such as 7+3 (cytarabine plus daunorubicin)—the combination has demonstrated improved response rates and survival in both newly diagnosed older adults with AML ineligible for intensive therapy and in various investigational settings for other malignancies[2][3][5][7]. This combination is FDA-approved for newly diagnosed AML in adults aged 75 or older or those with comorbidities precluding intensive chemotherapy[7].

Brand names

Venclexta + azacitidineVenclexta + decitabineVenclexta + low-dose cytarabine

Other names

venetoclax + azacitidinevenetoclax + decitabinevenetoclax + low-dose cytarabinevenetoclax + LDAC